 Manja Zec
Concepts (217)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fatty Acid Desaturases | 3 | 2021 | 31 | 1.890 |
Why?
| | Fatty Acids | 10 | 2021 | 450 | 1.800 |
Why?
| | Phospholipids | 6 | 2021 | 213 | 1.170 |
Why?
| | Juglans | 6 | 2025 | 8 | 1.130 |
Why?
| | Zinc | 5 | 2019 | 295 | 1.040 |
Why?
| | Polyphenols | 4 | 2021 | 20 | 0.980 |
Why?
| | Semicarbazones | 3 | 2014 | 3 | 0.880 |
Why?
| | Selenium Compounds | 2 | 2014 | 18 | 0.790 |
Why?
| | Coordination Complexes | 2 | 2014 | 13 | 0.790 |
Why?
| | Vitamin D | 3 | 2024 | 400 | 0.760 |
Why?
| | Photinia | 5 | 2021 | 5 | 0.720 |
Why?
| | Overweight | 4 | 2023 | 609 | 0.700 |
Why?
| | Vitamin D Deficiency | 2 | 2019 | 186 | 0.650 |
Why?
| | Arachidonic Acid | 1 | 2020 | 101 | 0.640 |
Why?
| | Recommended Dietary Allowances | 1 | 2019 | 16 | 0.620 |
Why?
| | Plasma | 1 | 2021 | 225 | 0.580 |
Why?
| | Dyslipidemias | 1 | 2019 | 181 | 0.540 |
Why?
| | Metabolic Syndrome | 4 | 2023 | 354 | 0.510 |
Why?
| | Cardiovascular Diseases | 7 | 2025 | 2168 | 0.510 |
Why?
| | Nuts | 4 | 2025 | 13 | 0.480 |
Why?
| | Erythrocytes | 2 | 2019 | 757 | 0.470 |
Why?
| | Nickel | 2 | 2014 | 64 | 0.460 |
Why?
| | Diet | 8 | 2025 | 1273 | 0.450 |
Why?
| | Antineoplastic Agents | 4 | 2016 | 2194 | 0.450 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 2145 | 0.380 |
Why?
| | Biomarkers | 4 | 2019 | 4271 | 0.370 |
Why?
| | Dietary Supplements | 3 | 2024 | 576 | 0.360 |
Why?
| | Fatty Acids, Omega-3 | 3 | 2025 | 142 | 0.360 |
Why?
| | Fructose | 5 | 2023 | 130 | 0.330 |
Why?
| | Neoplasm Metastasis | 1 | 2012 | 688 | 0.310 |
Why?
| | Linoleic Acid | 2 | 2019 | 44 | 0.280 |
Why?
| | Eating | 2 | 2021 | 389 | 0.270 |
Why?
| | Cadmium | 3 | 2014 | 69 | 0.270 |
Why?
| | Blood Pressure | 4 | 2025 | 1769 | 0.260 |
Why?
| | Cross-Sectional Studies | 6 | 2020 | 5868 | 0.250 |
Why?
| | Dietary Fats | 2 | 2019 | 314 | 0.250 |
Why?
| | Genotype | 2 | 2021 | 1833 | 0.230 |
Why?
| | Serbia | 3 | 2019 | 7 | 0.220 |
Why?
| | Diet, Mediterranean | 2 | 2022 | 28 | 0.220 |
Why?
| | Cardiovascular System | 1 | 2025 | 137 | 0.200 |
Why?
| | Fruit and Vegetable Juices | 3 | 2020 | 21 | 0.200 |
Why?
| | Plant Extracts | 3 | 2020 | 187 | 0.200 |
Why?
| | Hypertension | 2 | 2023 | 1263 | 0.200 |
Why?
| | Dietary Fats, Unsaturated | 2 | 2020 | 24 | 0.200 |
Why?
| | Obesity | 4 | 2023 | 3077 | 0.200 |
Why?
| | Obesity, Metabolically Benign | 1 | 2023 | 4 | 0.200 |
Why?
| | Feeding Behavior | 2 | 2019 | 684 | 0.190 |
Why?
| | HeLa Cells | 3 | 2014 | 650 | 0.190 |
Why?
| | Middle Aged | 14 | 2024 | 35875 | 0.190 |
Why?
| | Adult | 12 | 2024 | 40449 | 0.180 |
Why?
| | Nutritional Status | 3 | 2019 | 354 | 0.180 |
Why?
| | Group II Phospholipases A2 | 1 | 2021 | 10 | 0.180 |
Why?
| | Glucose Transporter Type 2 | 1 | 2021 | 16 | 0.170 |
Why?
| | Glucose Transporter Type 3 | 1 | 2021 | 15 | 0.170 |
Why?
| | Life Style | 2 | 2023 | 479 | 0.170 |
Why?
| | Gallic Acid | 1 | 2021 | 9 | 0.170 |
Why?
| | Sirtuin 1 | 1 | 2021 | 34 | 0.170 |
Why?
| | Glucose Transporter Type 1 | 1 | 2021 | 48 | 0.170 |
Why?
| | Catalase | 1 | 2021 | 130 | 0.170 |
Why?
| | Energy Intake | 3 | 2020 | 499 | 0.170 |
Why?
| | Eicosapentaenoic Acid | 1 | 2021 | 36 | 0.170 |
Why?
| | KATP Channels | 1 | 2020 | 17 | 0.160 |
Why?
| | Female | 17 | 2024 | 78271 | 0.160 |
Why?
| | Humans | 27 | 2025 | 144759 | 0.160 |
Why?
| | Hypothalamus | 1 | 2021 | 153 | 0.160 |
Why?
| | gamma-Linolenic Acid | 1 | 2019 | 2 | 0.160 |
Why?
| | Libya | 1 | 2019 | 4 | 0.160 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2020 | 98 | 0.160 |
Why?
| | Cholesterol | 2 | 2019 | 406 | 0.150 |
Why?
| | Transients and Migrants | 1 | 2019 | 27 | 0.150 |
Why?
| | Fatty Acids, Omega-6 | 1 | 2019 | 48 | 0.150 |
Why?
| | Calcium Channels | 1 | 2020 | 154 | 0.150 |
Why?
| | Magnesium | 1 | 2019 | 155 | 0.150 |
Why?
| | Cell Line, Tumor | 5 | 2014 | 3540 | 0.150 |
Why?
| | Sunlight | 1 | 2019 | 78 | 0.150 |
Why?
| | Copper | 1 | 2019 | 113 | 0.150 |
Why?
| | Male | 16 | 2024 | 72315 | 0.150 |
Why?
| | Body Weight | 2 | 2021 | 976 | 0.140 |
Why?
| | Metabolic Diseases | 1 | 2019 | 114 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2020 | 436 | 0.140 |
Why?
| | Alleles | 1 | 2021 | 879 | 0.130 |
Why?
| | Leukocytes, Mononuclear | 1 | 2020 | 573 | 0.130 |
Why?
| | Neoplasms | 3 | 2022 | 2875 | 0.130 |
Why?
| | Iron | 1 | 2019 | 359 | 0.130 |
Why?
| | Heart | 1 | 2021 | 636 | 0.130 |
Why?
| | Membrane Lipids | 2 | 2014 | 83 | 0.120 |
Why?
| | 8,11,14-Eicosatrienoic Acid | 1 | 2016 | 6 | 0.120 |
Why?
| | Placebos | 1 | 2017 | 192 | 0.120 |
Why?
| | Cytochromes c | 2 | 2014 | 53 | 0.120 |
Why?
| | Pharmacogenomic Variants | 1 | 2016 | 33 | 0.120 |
Why?
| | Gastrointestinal Microbiome | 1 | 2024 | 771 | 0.120 |
Why?
| | Rats | 5 | 2023 | 5597 | 0.120 |
Why?
| | Apoptosis | 4 | 2012 | 2430 | 0.120 |
Why?
| | Pyridines | 2 | 2011 | 605 | 0.120 |
Why?
| | Cognitive Dysfunction | 1 | 2022 | 461 | 0.120 |
Why?
| | Caspase 3 | 2 | 2014 | 238 | 0.120 |
Why?
| | Cell Cycle | 3 | 2014 | 596 | 0.110 |
Why?
| | Cause of Death | 1 | 2018 | 471 | 0.110 |
Why?
| | Rats, Wistar | 3 | 2021 | 451 | 0.110 |
Why?
| | Hippocampus | 1 | 2021 | 965 | 0.110 |
Why?
| | Pharmacogenetics | 1 | 2016 | 172 | 0.110 |
Why?
| | Mannans | 1 | 2014 | 5 | 0.110 |
Why?
| | Obesity, Abdominal | 1 | 2014 | 46 | 0.110 |
Why?
| | Taste | 1 | 2017 | 239 | 0.110 |
Why?
| | Beverages | 1 | 2014 | 69 | 0.110 |
Why?
| | Adiposity | 1 | 2019 | 543 | 0.110 |
Why?
| | Cations, Divalent | 1 | 2014 | 47 | 0.100 |
Why?
| | Inhibitory Concentration 50 | 1 | 2014 | 91 | 0.100 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1720 | 0.100 |
Why?
| | Organ Specificity | 1 | 2014 | 312 | 0.100 |
Why?
| | Necrosis | 1 | 2014 | 244 | 0.090 |
Why?
| | Incidence | 1 | 2019 | 2879 | 0.090 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2012 | 56 | 0.090 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2012 | 132 | 0.090 |
Why?
| | Precision Medicine | 1 | 2016 | 457 | 0.090 |
Why?
| | RNA, Messenger | 1 | 2020 | 2832 | 0.090 |
Why?
| | Breast | 1 | 2012 | 158 | 0.090 |
Why?
| | Intercalating Agents | 1 | 2011 | 4 | 0.090 |
Why?
| | Malonates | 1 | 2011 | 9 | 0.090 |
Why?
| | Animals | 9 | 2025 | 38058 | 0.090 |
Why?
| | Cobalt | 1 | 2011 | 53 | 0.080 |
Why?
| | Azides | 1 | 2011 | 47 | 0.080 |
Why?
| | Selenium | 1 | 2011 | 49 | 0.080 |
Why?
| | Antioxidants | 1 | 2014 | 549 | 0.080 |
Why?
| | Angiogenesis Inhibitors | 1 | 2012 | 237 | 0.080 |
Why?
| | Reactive Oxygen Species | 1 | 2014 | 621 | 0.080 |
Why?
| | Cell Survival | 1 | 2014 | 1098 | 0.080 |
Why?
| | Organoselenium Compounds | 1 | 2010 | 11 | 0.080 |
Why?
| | Metals | 1 | 2011 | 142 | 0.080 |
Why?
| | Heart Failure | 1 | 2023 | 2323 | 0.080 |
Why?
| | Biomarkers, Tumor | 1 | 2016 | 1313 | 0.070 |
Why?
| | Risk Factors | 5 | 2023 | 10779 | 0.070 |
Why?
| | Breast Neoplasms | 2 | 2012 | 2452 | 0.070 |
Why?
| | Gene Expression | 1 | 2014 | 1490 | 0.070 |
Why?
| | South Africa | 2 | 2019 | 261 | 0.070 |
Why?
| | Cell Movement | 1 | 2012 | 965 | 0.070 |
Why?
| | Double-Blind Method | 2 | 2024 | 2029 | 0.070 |
Why?
| | Cell Line | 1 | 2012 | 2882 | 0.060 |
Why?
| | Aged | 4 | 2021 | 25913 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 6048 | 0.060 |
Why?
| | Phytotherapy | 2 | 2019 | 74 | 0.060 |
Why?
| | Epithelial Cells | 1 | 2011 | 1125 | 0.050 |
Why?
| | Mitochondria | 1 | 2011 | 984 | 0.050 |
Why?
| | Cholecalciferol | 1 | 2024 | 60 | 0.050 |
Why?
| | Healthy Volunteers | 1 | 2024 | 215 | 0.050 |
Why?
| | Cations | 1 | 2023 | 82 | 0.050 |
Why?
| | PPAR alpha | 1 | 2022 | 54 | 0.050 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 2022 | 54 | 0.050 |
Why?
| | Body Mass Index | 2 | 2023 | 2438 | 0.040 |
Why?
| | Feces | 1 | 2024 | 513 | 0.040 |
Why?
| | Adenosine Triphosphate | 1 | 2023 | 498 | 0.040 |
Why?
| | Sodium-Calcium Exchanger | 1 | 2020 | 14 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2021 | 769 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2019 | 131 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 99 | 0.040 |
Why?
| | Waist-Hip Ratio | 1 | 2019 | 37 | 0.040 |
Why?
| | Cell Death | 1 | 2020 | 383 | 0.030 |
Why?
| | Waist Circumference | 1 | 2019 | 139 | 0.030 |
Why?
| | Fruit | 1 | 2019 | 152 | 0.030 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2011 | 630 | 0.030 |
Why?
| | Mice | 2 | 2012 | 18339 | 0.030 |
Why?
| | Bacteria | 1 | 2024 | 889 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2021 | 474 | 0.030 |
Why?
| | Centralized Hospital Services | 1 | 2016 | 6 | 0.030 |
Why?
| | Aspartate Aminotransferases | 1 | 2017 | 85 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 2089 | 0.030 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2016 | 32 | 0.030 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2016 | 35 | 0.030 |
Why?
| | Platelet Aggregation | 1 | 2017 | 105 | 0.030 |
Why?
| | Alanine Transaminase | 1 | 2017 | 151 | 0.030 |
Why?
| | Regression Analysis | 1 | 2019 | 1003 | 0.030 |
Why?
| | Platelet Activation | 1 | 2017 | 104 | 0.030 |
Why?
| | Nutrition Surveys | 1 | 2018 | 282 | 0.030 |
Why?
| | Prospective Studies | 2 | 2019 | 7990 | 0.030 |
Why?
| | Homozygote | 1 | 2016 | 199 | 0.030 |
Why?
| | Phosphorylation | 1 | 2020 | 1732 | 0.030 |
Why?
| | Glucose | 1 | 2021 | 1047 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 341 | 0.030 |
Why?
| | Heterozygote | 1 | 2016 | 315 | 0.030 |
Why?
| | Nitric Oxide | 1 | 2020 | 897 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2016 | 406 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 253 | 0.030 |
Why?
| | Gene Frequency | 1 | 2016 | 481 | 0.030 |
Why?
| | Creatinine | 1 | 2017 | 506 | 0.030 |
Why?
| | Triglycerides | 1 | 2017 | 520 | 0.030 |
Why?
| | Phenotype | 1 | 2023 | 3162 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1266 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1325 | 0.030 |
Why?
| | Polymorphism, Genetic | 1 | 2016 | 612 | 0.030 |
Why?
| | Transcriptome | 1 | 2020 | 1045 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2925 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2016 | 627 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2020 | 2496 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3604 | 0.020 |
Why?
| | Artemia | 1 | 2011 | 8 | 0.020 |
Why?
| | Circular Dichroism | 1 | 2011 | 150 | 0.020 |
Why?
| | Pilot Projects | 1 | 2017 | 1886 | 0.020 |
Why?
| | Spectrum Analysis | 1 | 2011 | 93 | 0.020 |
Why?
| | Spectrometry, Fluorescence | 1 | 2011 | 168 | 0.020 |
Why?
| | Membrane Potentials | 1 | 2011 | 280 | 0.020 |
Why?
| | Risk Assessment | 1 | 2019 | 3671 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 8265 | 0.020 |
Why?
| | Registries | 1 | 2018 | 2385 | 0.020 |
Why?
| | Blotting, Western | 1 | 2011 | 1187 | 0.020 |
Why?
| | Molecular Structure | 1 | 2010 | 499 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2010 | 492 | 0.020 |
Why?
| | Cohort Studies | 1 | 2019 | 5960 | 0.020 |
Why?
| | Kinetics | 1 | 2011 | 1627 | 0.020 |
Why?
| | Young Adult | 1 | 2024 | 14105 | 0.020 |
Why?
| | Signal Transduction | 1 | 2020 | 5226 | 0.020 |
Why?
| | Time Factors | 1 | 2016 | 7173 | 0.010 |
Why?
| | Mutation | 1 | 2016 | 4089 | 0.010 |
Why?
| | DNA | 1 | 2011 | 1463 | 0.010 |
Why?
| | Adolescent | 1 | 2021 | 22428 | 0.010 |
Why?
| | Child | 1 | 2021 | 22633 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2016 | 11679 | 0.010 |
Why?
| | United States | 1 | 2018 | 15966 | 0.010 |
Why?
|
|
Zec's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|